MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.810
-0.150
-5.07%
After Hours: 2.800 -0.01 -0.36% 19:35 01/21 EST
OPEN
3.000
PREV CLOSE
2.960
HIGH
3.040
LOW
2.800
VOLUME
1.81M
TURNOVER
--
52 WEEK HIGH
9.89
52 WEEK LOW
2.800
MARKET CAP
580.94M
P/E (TTM)
-7.6172
1D
5D
1M
3M
1Y
5Y
Precigen provides pipeline updates for 2022
Precigen (NASDAQ:PGEN) presented pipeline updates at the 40th Annual J.P. Morgan Healthcare Conference. PRGN-3006 UltraCAR-T is being evaluated in a phase 1/1b trial to treat patients with relapsed or refractory AML or
Seekingalpha · 01/12 21:55
Precigen Announced Enrollment Completion For Dose Level 3 Of Lymphodepletion Cohort, Provides Pipeline Update At J.P. Morgan Health Conference
PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML) Overview: PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR
Benzinga · 01/12 21:32
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.P. Morgan Healthcare Conf...
PR Newswire · 01/12 21:30
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates hig...
Zacks · 01/11 15:00
Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will present a corp...
PR Newswire · 01/05 21:05
3 Synthetic Biology Stocks in Focus With Strong Potential
Zacks.com · 01/04 00:30
Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients
Precigen Inc (NASDAQ: PGEN) 
Benzinga · 12/14/2021 13:08
Precigen interim early-stage data on AML therapy shows 50% objective response rate
Precigen's (NASDAQ:PGEN) acute myeloid leukemia candidate PRGN-3006 UltraCAR-T demonstrated an objective response rate of 50% based on six patients. In the lymphodeletion cohort, there were two complete responses at the two
Seekingalpha · 12/13/2021 22:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PGEN stock price target is 12.20 with a high estimate of 17.00 and a low estimate of 6.00.
High17.00
Average12.20
Low6.00
Current 2.810
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 267
Institutional Holdings: 141.81M
% Owned: 68.59%
Shares Outstanding: 206.74M
TypeInstitutionsShares
Increased
46
1.78M
New
35
2.93M
Decreased
45
8.36M
Sold Out
11
182.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Chief Financial Officer
Harry Thomasian
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
Declaration Date
Dividend Per Share
Ex-Div Date
06/08/2015
Dividend USD 0.162
06/09/2015
About PGEN
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. The Company is offering a class of microbe-based biopharmaceuticals that enable the expression and local delivery of disease-modifying therapeutics. Precigen is using precision technology to target intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The Company also focused on studying life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. The Company’s subsidiaries include PGEN Therapeutics, Inc., Precigen ActoBio, Inc., Exemplar Genetics, LLC and Trans Ova Genetics, L.C.

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.